Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

Cliff Battram, Steven J. Charlton, Bernard Cuenoud, Mark R. Dowling, Robin A. Fairhurst, David Farr, John R. Fozard, Juliet R. Leighton-Davies, Christine A. Lewis, Lorraine McEvoy, Robert J. Turner and Alexandre Trifilieff
Journal of Pharmacology and Experimental Therapeutics May 2006, 317 (2) 762-770; DOI: https://doi.org/10.1124/jpet.105.098251
Cliff Battram
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven J. Charlton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Cuenoud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark R. Dowling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin A. Fairhurst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Farr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. Fozard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet R. Leighton-Davies
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine A. Lewis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorraine McEvoy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Turner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Trifilieff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 372 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 372, Issue 1
1 Jan 2020
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

Cliff Battram, Steven J. Charlton, Bernard Cuenoud, Mark R. Dowling, Robin A. Fairhurst, David Farr, John R. Fozard, Juliet R. Leighton-Davies, Christine A. Lewis, Lorraine McEvoy, Robert J. Turner and Alexandre Trifilieff
Journal of Pharmacology and Experimental Therapeutics May 1, 2006, 317 (2) 762-770; DOI: https://doi.org/10.1124/jpet.105.098251

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

Cliff Battram, Steven J. Charlton, Bernard Cuenoud, Mark R. Dowling, Robin A. Fairhurst, David Farr, John R. Fozard, Juliet R. Leighton-Davies, Christine A. Lewis, Lorraine McEvoy, Robert J. Turner and Alexandre Trifilieff
Journal of Pharmacology and Experimental Therapeutics May 1, 2006, 317 (2) 762-770; DOI: https://doi.org/10.1124/jpet.105.098251
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • ATP via P2X2/3 Facilitates ACh Release in the Human Bladder
  • DMOG, a prolyl hydroxylase inhibitor, increases hemoglobin levels without exacerbating hypertension and renal injury in salt-sensitive hypertensive rats.
  • Liver-Specific PHD Inhibitor
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics